rokitamycin and Otitis-Media-with-Effusion

Six cases of otitis media with effusion associated with Chlamydia pneumoniae, a currently recognized respiratory tract pathogen, are presented. The organism was isolated from the middle ear fluids and serological evidence confirmed it as the infectious agent. The study population is small; however, these reports suggest C. pneumoniae as a causative agent of middle ear diseases.

Topics: Adult; Child; Child, Preschool; Chlamydia Infections; Chlamydophila pneumoniae; Female; Humans; Male; Middle Aged; Miocamycin; Otitis Media with Effusion

Dry syrup of Rokitamycin (RKM.DS), a new macrolide antibiotic with 16-membered ring developed by Toyo Jozo Co., Ltd., was used on cases of upper deep cervical lymphadenitis (UDCL) and of otitis media with exudatives (OME) likely caused by chlamydia infections, and its clinical effects were investigated. 1) In four cases of UDCL (C. psittaci infections), daily doses of 20.0-28.6 mg/kg were administered for 10-42 consecutive days and good efficacies were observed with two cases of excellent results and two cases of good results. 2) In one case of OME (C. trachomatis infection) a daily dose of 30.0 mg/kg was administered for 15 consecutive days and good effectiveness was observed. 3) No side effect was observed in any of the cases. From the above results, it became clear that RKM.DS could effectively used as a therapeutic agent for UDCL and OME in children.

Topics: Child; Child, Preschool; Chlamydia Infections; Chlamydia trachomatis; Chlamydophila psittaci; Drug Evaluation; Female; Humans; Leucomycins; Lymphadenitis; Male; Miocamycin; Neck; Otitis Media with Effusion; Psittacosis